Biogen - BIIB Stock Forecast, Price & News

25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 6 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.

25 analysts have issued 12-month price targets for Biogen's shares. Their BIIB share price forecasts range from $247.00 to $370.00. On average, they expect the company's stock price to reach $319.00 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.

Biogen's stock was trading at $276.92 at the beginning of the year. Since then, BIIB shares have increased by 0.4% and is now trading at $278.03.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our BIIB earnings forecast.

Biogen Inc. (NASDAQ:BIIB) released its earnings results on Wednesday, February, 15th. The biotechnology company reported $4.05 earnings per share for the quarter, topping analysts' consensus estimates of $3.48 by $0.57. The biotechnology company earned $2.54 billion during the quarter, compared to analyst estimates of $2.44 billion. Biogen had a trailing twelve-month return on equity of 20.96% and a net margin of 29.95%. The company's revenue was down 6.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.39 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include VanEck Biotech ETF (BBH), Invesco Dynamic Biotechnology & Genome ETF (PBE), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), Psyk Etf (PSYK), iShares Neuroscience and Healthcare ETF (IBRN), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and Invesco Dynamic Pharmaceuticals ETF (PJP).

Biogen updated its FY 2023 earnings guidance on Wednesday, February, 15th. The company provided EPS guidance of $15.00-$16.00 for the period, compared to the consensus earnings per share estimate of $15.72. The company issued revenue guidance of -.

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIIB stock can currently be purchased for approximately $278.03.

Biogen (NASDAQ:BIIB) has a market capitalization of $40.17 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $20.93 on an earnings per share basis.

The company employs 8,725 workers across the globe.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.